The historic rise of Viagra has long been a benchmark of pharmaceutical success, however its position within the broader sector now triggers questions about potential returns . Copycat versions are undercutting patent protection , prompting concerns that investing in companies significantly dependent to Viagra's once-dominant standing could be a sp